Glucocorticoid Treatment in Severe Asthma

María Florencia Pilia; David Espejo-Castellanos; Christian Romero-Mesones; Xavier Muñoz-Gall; Iñigo Ojanguren-Arranz

doi:10.1055/a-2746-4469

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med
DOI: 10.1055/a-2746-4469

Review Article

Glucocorticoid Treatment in Severe Asthma

Autor*innen

María Florencia Pilia

¹Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain

²Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

³CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
David Espejo-Castellanos

¹Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain

²Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

³CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
Christian Romero-Mesones

¹Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain

²Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

³CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
Xavier Muñoz-Gall

¹Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain

²Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

³CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain

⁴Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
Iñigo Ojanguren-Arranz

¹Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain

²Pneumology Department, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

³CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain

⁴Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain

Abstract

Severe asthma affects approximately 3% to 10% of the asthmatic population and is characterized by persistent symptoms and frequent exacerbations despite high-intensity therapy. Historically, glucocorticoids (GCs) have been the mainstay of treatment due to their broad anti-inflammatory effects. However, long-term systemic GC use is associated with substantial toxicity and heterogeneous clinical response, largely influenced by underlying inflammatory endotypes. Type 2 (T2) asthma, marked by eosinophilia and cytokines such as IL-4, IL-5, and IL-13, generally responds well to GCs. In contrast, non-T2 phenotypes, often associated with neutrophilic inflammation, obesity, or smoking, exhibit GC resistance. Molecular mechanisms underlying GC resistance include GRβ overexpression, impaired GRα nuclear translocation via mitogen-activated protein kinase (MAPK) activation, and histone deacetylase-2 (HDAC2) inactivation by oxidative stress. Therapeutic strategies for severe asthma involve maximizing inhaled corticosteroids (ICSs) and adding long-acting bronchodilators or biologics before considering maintenance oral corticosteroids (OCSs). Despite these guidelines, OCS overuse remains common, with many patients exposed to cumulative doses associated with severe adverse effects. These include osteoporosis, diabetes, infections, neuropsychiatric symptoms, and adrenal suppression. Therefore, reducing systemic GC exposure is a key objective in modern asthma management. Biologic therapies targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab), IL-5Rα (benralizumab), IL-4Rα (dupilumab), and thymic stromal lymphopoietin (tezepelumab) have shown substantial OCS-sparing effects in clinical trials, enabling dose reduction or discontinuation in many patients with steroid-dependent asthma. These agents, aligned with precision medicine principles, allow for phenotype-specific treatment and improved safety profiles. Future efforts should focus on improving biomarker-driven treatment selection, expanding non-T2 therapeutic options, and implementing steroid stewardship protocols. In conclusion, while GCs remain essential for acute exacerbations and as bridging therapy, their chronic use should be minimized. Biologic therapies offer a transformative opportunity to reduce GC burden, improving long-term outcomes and quality of life in patients with severe asthma.

Keywords

glucocorticoid resistance - biologic therapies - oral corticosteroids - severe asthma

Volltext

Referenzen

References
1 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 . Accessed January 2, 2025 at: https://ginasthma.org/
2 Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135 (04) 896-902
3 Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 2006; 15 (06) 326-331
4 Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med 2017; 377 (10) 965-976
5 Galeone C, Scelfo C, Bertolini F. et al. Precision medicine in targeted therapies for severe asthma: Is there any place for “omics” technology?. BioMed Res Int 2018; 2018: 4617565
6 Heaney LG, Perez de Llano L, Al-Ahmad M. et al. Eosinophilic and noneosinophilic asthma: An expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest 2021; 160: 814-830 . Elsevier Inc.
7 Porsbjerg C, Nieto-Fontarigo JJ, Cerps S. et al. Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic. Eur Respir J 2022; 60 (01) 2102333
8 Bourdin A, Brusselle G, Couillard S. et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract 2024; 12 (04) 809-823
9 Ricciardolo FLM, Sprio AE, Baroso A. et al. Characterization of t2-low and t2-high asthma phenotypes in real-life. Biomedicines 2021; 9 (11) 1684
10 Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019; 56 (02) 219-233
11 Rupani H, Kyyaly MA, Azim A. et al. Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status. J Allergy Clin Immunol Pract 2023; 11 (09) 2812-2821.e4
12 Henderson I, Caiazzo E, McSharry C, Guzik TJ, Maffia P. Why do some asthma patients respond poorly to glucocorticoid therapy?. Pharmacol Res 2020; 160: 105189
13 Hasan MM, Tory S. Association between glucocorticoid receptor beta and steroid resistance: A systematic review. Immun Inflamm Dis 2024; 12 (01) e1137
14 Ramos-Ramírez P, Tliba O. Glucocorticoid receptor β (GRβ): Beyond its dominant-negative function. Int J Mol Sci 2021; 22 (07) 3649
15 Kim CK, Agrawal DK. Glucocorticoid insensitivity in severe asthma: Underlying molecular mechanisms, challenges, and emerging therapies. Arch Intern Med Res 2025; 8 (02) 107-120
16 Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci 2019; 40 (01) 38-49
17 Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131 (03) 636-645
18 Ye Q, He XO, D'Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther 2017;3(1)
19 Daley-Yates PT, Aggarwal B, Plank M. Pharmacological basis of differences in dose response, dose equivalence, and duration of action of inhaled corticosteroids. Adv Ther 2024; 41 (05) 1995-2009
20 Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: Results from a meta-analysis. Ann Allergy Asthma Immunol 2007; 98 (03) 225-238
21 Domínguez-Ortega J, Delgado Romero J, Muñoz Gall X, Marco A, Blanco-Aparicio M. Use of systemic glucocorticoids for the treatment of severe asthma: Spanish Multidisciplinary Consensus [In Spanish]. Open Respir Arch 2022; 4 (04) 100202
22 Guía Española para el Manejo del Asma: GEMA 5.4. ISBN: 978-84-19832-56-6. https://www.separ.es/gema-5.5-asma
23 Mein SA, Ferrera MC. Management of asthma and COPD exacerbations in adults in the ICU. CHEST Crit Care 2025; 3 (01) 100107
24 Littenberg B, Gluck EH. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. N Engl J Med 1986; 314 (03) 150-152
25 Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology 2020; 25 (02) 161-172
26 Canonica GW, Porsbjerg C, Price DB. et al. Burden of oral corticosteroid use in severe asthma: Challenges and opportunities. Allergy 2025; 80 (08) 2113-2127
27 Bleecker ER, Menzies-Gow AN, Price DB. et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med 2020; 201 (03) 276-293
28 Gurnell M, Heaney LG, Price D, Menzies-Gow A. Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. J Intern Med 2021; 290 (02) 240-256
29 Heffler E, Blasi F, Paggiaro P, Canonica GW. Costs of oral corticosteroid use in patients with severe asthma with/without chronic rhinosinusitis with nasal polyps: Data from the Italian SANI Registry. Adv Ther 2025; 42 (02) 1196-1206
30 Zeiger R, Sullivan P, Chung Y, Kreindler JL, Zimmerman NM, Tkacz J. Systemic corticosteroid-related complications and costs in adults with persistent asthma. J Allergy Clin Immunol Pract 2020; 8 (10) 3455-3465.e13
31 Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: A focused review of the impact data in the literature. Eur Respir J 2018; 52 (04) 1800703
32 Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm 2016; 22 (07) 833-47
33 Casale TB, Corbridge T, Germain G. et al. Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma. Allergy Asthma Clin Immunol 2024; 20 (01) 25
34 Wadhwa R, Dua K, Adcock IM, Horvat JC, Kim RY, Hansbro PM. Cellular mechanisms underlying steroid-resistant asthma. Eur Respir Rev 2019; 28 (153) 190096
35 Milara J, Morell A, Roger I, Montero P, Cortijo J. Mechanisms underlying corticosteroid resistance in patients with asthma: A review of current knowledge. Expert Rev Respir Med 2023; 17 (08) 701-715
36 Liu R, Bai J, Xu G. et al. Multi-allergen challenge stimulates steriod-resistant airway inflammation via NF-κB-mediated IL-8 expression. Inflammation 2013; 36 (04) 845-854
37 Gibson PG, Yang IA, Upham JW. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial. Lancet 2017; 390 (10095): 659-668
38 Salem IH, Boulet L-P, Biardel S. et al. Long-term effects of bronchial thermoplasty on airway smooth muscle and reticular basement membrane thickness in severe asthma. Ann Am Thorac Soc 2016; 13 (08) 1426-1428
39 Liu T, Woodruff PG, Zhou X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur Respir J 2024; 64 (02) 2300826
40 Bel EH, Wenzel SE, Thompson PJ. et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371 (13) 1189-1197
41 Nair P, Wenzel S, Rabe KF. et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376 (25) 2448-2458
42 Castro M, Corren J, Pavord ID. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378 (26) 2486-2496
43 Wechsler ME, Menzies-Gow A, Brightling CE. et al; SOURCE study group. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med 2022; 10 (07) 650-660
44 Siergiejko Z, Świebocka E, Smith N. et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin 2011; 27 (11) 2223-2228
45 Jackson DJ, Heaney LG, Humbert M. et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): A randomised, multicentre, open-label, phase 4 study. Lancet 2024; 403 (10423): 271-281
46 Menzies-Gow A, Corren J, Bel EH. et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res 2019; 5 (03) 00009-2019
47 Rabe KF, Nair P, Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378 (26) 2475-2485
48 Jackson DJ, Lugogo N, Gurnell M. et al. Tezepelumab reduces and eliminates OCS use in OCS-dependent patients with severe asthma: Primary results from the Phase 3b WAYFINDER Study. Am J Respir Crit Care Med 2025; 211 (111) A5231-A5231